SCHEMBL4901212

SCHEMBL4901212

CCCNS(=O)(=O)c1ccc2c(c1)C(=NNc1ccccc1[N+](=O)[O-])C(=O)N2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.44
MAPT P10636 9/20 0.44
HTT P42858 2/20 0.44
LMNA P02545 4/20 0.41
MGAT2 Q10469 3/20 0.40
MGAT1 P26572 2/20 0.39
POLB P06746 2/20 0.39
MAPK1 P28482 4/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
GAA P10253 1/20 0.38
MGAT3 Q09327 1/20 0.38
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA12 O43570 1/20 0.37
CA9 Q16790 1/20 0.37
TDP1 Q9NUW8 3/20 0.37
MEN1 O00255 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4907918 1.00 ALDH1A1 (0.44) ALDH1A1MAPTHTTLMNAMGAT2
SCHEMBL14111856 0.90 ALDH1A1 (0.46) ALDH1A1MAPTHTTLMNAMGAT2
SCHEMBL14111849 0.90 ALDH1A1 (0.48) ALDH1A1MAPTHTTLMNAMGAT2
SCHEMBL14111946 0.89 ALDH1A1 (0.43) ALDH1A1MAPTHTTLMNASMN1; SMN2
SCHEMBL14111931 0.86 MGAT2 (0.52) ALDH1A1MAPTLMNAMGAT2MGAT1
SCHEMBL4909465 0.85 MGAT2 (0.38) ALDH1A1MAPTHTTLMNAMGAT2
SCHEMBL4909460 0.85 MGAT2 (0.38) ALDH1A1MAPTHTTLMNAMGAT2
SCHEMBL4901201 0.85 PTPN11 (0.42) ALDH1A1MAPTHTTLMNAMGAT2
SCHEMBL4901208 0.85 PTPN11 (0.42) ALDH1A1MAPTHTTLMNAMGAT2
SCHEMBL4413418 0.84 PTPN1 (0.47) ALDH1A1MAPTHTTLMNAMGAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8987474-B2 Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs UNIVERSITY OF SOUTH FLORIDA (US) 2015-03-24 US disclosed
US-20080176309-A1 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer UNIVERSITY OF SOUTH FLORIDA (US) 2008-07-24 US disclosed
WO-2007117699-A2 INHIBITION OF SHP2/PTPN11 PROTEIN TYROSINE PHOSPHATASE BY NSC-87877, NSC-117199 AND THEIR ANALOGS UNIVERSITY OF SOUTH FLORIDA (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176309-A1 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer PTPN7, PTPN1, PTPN2 ALDH1A1 3859/4885MAPT 4753/4885HTT 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.